High protein expression of YAP1 and SRC are commonly observed in high Gleason grade prostate cancer clinical specimens, and positively correlates with a poor prognosis and metastatic burden [298,299], indicating that YAP1 and SRC may provide valuable therapeutic targets and warrant further investigation. The gene discussed is SRC; the disease is prostate cancer.